{"_links":{"self":[{"href":"/project/GID-HUB10003"}]},"_embedded":{"nice.indev:panel-list":{"_links":{"self":[{}]},"ETag":null}},"ETag":"01000000-0000-0001-0000-00000000037C","Summary":null,"Description":null,"ReferralDate":null,"SuspendDiscontinuedReason":null,"SuspendDiscontinuedUrl":null,"SuspendDiscontinuedUrlText":null,"LegacyModel":false,"ProductReference":null,"EvidenceAssessmentGroup":null,"Alert":null,"Content":"<p>This webpage covers NICE guidelines on breast cancer. The table below presents the guidelines alphabetically with links to the&nbsp;<a href=\"https://www.nice.org.uk/guidance/ng101/resources/2023-surveillance-of-early-and-locally-advanced-breast-cancer-diagnosis-and-management-nice-guideline-ng101-and-advanced-breast-cancer-diagnosis-and-treatment-nice-guideline-cg81-11321031709/chapter/Surveillance-decision\">surveillance report</a>&nbsp;where relevant. Updates planned or in progress and areas being&nbsp;<a href=\"https://www.nice.org.uk/hub/indevelopment/gid-hub10003/#methods\">actively monitored</a>&nbsp;are listed for each guideline and there are links to the individual update pages for more information.</p>\r\n<h2>Guidelines</h2>\r\n<table style=\"float: left;\" border=\"1\" width=\"100%\">\r\n<thead>\r\n<tr>\r\n<td width=\"35%\">\r\n<p><strong>Guideline</strong></p>\r\n</td>\r\n<td width=\"33%\">\r\n<p><strong>Updates planned or in progress</strong></p>\r\n</td>\r\n<td width=\"30%\">\r\n<p><strong>Areas we&rsquo;re&nbsp;<a href=\"https://www.nice.org.uk/hub/indevelopment/gid-hub10003/#methods\">actively monitoring</a></strong></p>\r\n</td>\r\n</tr>\r\n</thead>\r\n<tbody>\r\n<tr>\r\n<td width=\"35%\">\r\n<p><a href=\"https://www.nice.org.uk/guidance/CG81\">Advanced breast cancer: diagnosis and treatment</a>&nbsp;(CG81)</p>\r\n</td>\r\n<td width=\"33%\">\r\n<p>Updates in progress</p>\r\n<ul>\r\n<li><a href=\"https://www.nice.org.uk/guidance/indevelopment/gid-ng10415\">Lymphoedema in all people with breast cancer</a>&nbsp;(see also early and locally advanced breast cancer)</li>\r\n</ul>\r\n<p>Updates planned</p>\r\n<ul>\r\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/resources/2023-surveillance-of-early-and-locally-advanced-breast-cancer-diagnosis-and-management-nice-guideline-ng101-and-advanced-breast-cancer-diagnosis-and-treatment-nice-guideline-cg81-11321031709/chapter/surveillance-decision#chemotherapy-for-advanced-breast-cancer\">Chemotherapy for advanced breast cancer</a></li>\r\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/resources/2023-surveillance-of-early-and-locally-advanced-breast-cancer-diagnosis-and-management-nice-guideline-ng101-and-advanced-breast-cancer-diagnosis-and-treatment-nice-guideline-cg81-11321031709/chapter/surveillance-decision#biological-therapy-for-advanced-breast-cancer\">Biological therapy for advanced breast cancer</a></li>\r\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/resources/2023-surveillance-of-early-and-locally-advanced-breast-cancer-diagnosis-and-management-nice-guideline-ng101-and-advanced-breast-cancer-diagnosis-and-treatment-nice-guideline-cg81-11321031709/chapter/surveillance-decision#ovarian-function-suppression-for-premenopausal-and-perimenopausal-women-with-oestrogen\">Ovarian function suppression for premenopausal and perimenopausal women with oestrogen receptor-positive early, locally advanced and advanced breast cancer&nbsp;</a>&nbsp;(see also early and locally advanced breast cancer)</li>\r\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/resources/2023-surveillance-of-early-and-locally-advanced-breast-cancer-diagnosis-and-management-nice-guideline-ng101-and-advanced-breast-cancer-diagnosis-and-treatment-nice-guideline-cg81-11321031709/chapter/surveillance-decision#menopausal-symptoms-in-all-people-with-breast-cancer\">Menopausal symptoms in all people with breast cancer</a>&nbsp;(see also early and locally advanced breast cancer)</li>\r\n</ul>\r\n</td>\r\n<td width=\"30%\">\r\n<p><a href=\"https://www.nice.org.uk/guidance/cg81/chapter/Recommendations#chemotherapy\">Chemotherapy for advanced breast cancer</a></p>\r\n<p><a href=\"https://www.nice.org.uk/guidance/cg81/chapter/Recommendations#systemic-disease-modifying-therapy\">Endocrine therapy for advanced breast cancer</a></p>\r\n<p><a href=\"https://www.nice.org.uk/guidance/cg81/chapter/Recommendations#systemic-disease-modifying-therapy\">Biological therapy for advanced breast cancer</a></p>\r\n</td>\r\n</tr>\r\n<tr>\r\n<td width=\"35%\">\r\n<p><a href=\"https://www.nice.org.uk/guidance/NG101\">Early and locally advanced breast cancer: diagnosis and management</a>&nbsp;(NG101)</p>\r\n</td>\r\n<td width=\"33%\">\r\n<p>Updates in progress</p>\r\n<ul>\r\n<li><a href=\"https://www.nice.org.uk/guidance/indevelopment/gid-ng10402\">Further breast surgery after breast-conserving surgery based on tissue margins</a></li>\r\n<li><a href=\"https://www.nice.org.uk/guidance/indevelopment/gid-ng10419\">Neoadjuvant chemotherapy for people with HER2-positive invasive breast cancer and triple-negative invasive breast cancer (early and locally advanced breast cancer</a>)</li>\r\n<li><a href=\"https://www.nice.org.uk/guidance/indevelopment/gid-ng10415\">Lymphoedema in all people with breast cancer</a>&nbsp;(see also advanced breast cancer)</li>\r\n<li><a href=\"https://www.nice.org.uk/guidance/indevelopment/gid-ng10419\">Platinum-based neoadjuvant chemotherapy regimens for people with triple-negative invasive early and locally advanced breast cancer</a></li>\r\n<li><a href=\"https://www.nice.org.uk/guidance/indevelopment/gid-ng10419\">Ovarian function suppression for premenopausal and perimenopausal women with oestrogen receptor-positive early, locally advanced and advanced breast cancer</a>&nbsp;(see also advanced breast cancer)</li>\r\n</ul>\r\n<p>Updates planned</p>\r\n<ul>\r\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/resources/2023-surveillance-of-early-and-locally-advanced-breast-cancer-diagnosis-and-management-nice-guideline-ng101-and-advanced-breast-cancer-diagnosis-and-treatment-nice-guideline-cg81-11321031709/chapter/surveillance-decision#genetic-testing-for-people-with-early-and-locally-advanced-breast-cancer\">Genetic testing for people with early and locally advanced breast cancer</a></li>\r\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/resources/2023-surveillance-of-early-and-locally-advanced-breast-cancer-diagnosis-and-management-nice-guideline-ng101-and-advanced-breast-cancer-diagnosis-and-treatment-nice-guideline-cg81-11321031709/chapter/surveillance-decision#menopausal-symptoms-in-all-people-with-breast-cancer\">Menopausal symptoms in all people with breast cancer</a>&nbsp;(see also advanced breast cancer)</li>\r\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/resources/2023-surveillance-of-early-and-locally-advanced-breast-cancer-diagnosis-and-management-nice-guideline-ng101-and-advanced-breast-cancer-diagnosis-and-treatment-nice-guideline-cg81-11321031709/chapter/surveillance-decision#psychological-support-for-all-people-with-breast-cancer\">Psychological support for all people with breast cancer</a></li>\r\n</ul>\r\n</td>\r\n<td width=\"30%\">\r\n<p><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#surgery-to-the-breast\">Surgery to the breast</a></p>\r\n<p><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#surgery-to-the-axilla\">Surgery to the axilla</a></p>\r\n<p><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#endocrine-therapy\">Endocrine therapy</a></p>\r\n<p><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#primary-systemic-therapy\">Neoadjuvant endocrine therapy</a></p>\r\n<p><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#adjuvant-chemotherapy-for-invasive-breast-cancer\">Adjuvant chemotherapy for early and locally advanced breast cancer</a></p>\r\n<p><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#primary-systemic-therapy\">Neoadjuvant chemotherapy for early and locally advanced breast cancer</a></p>\r\n<p><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#adjuvant-chemotherapy-for-invasive-breast-cancer\">Biological therapy for early and locally advanced breast cancer</a></p>\r\n<p><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#radiotherapy\">Radiotherapy after breast-conserving surgery</a></p>\r\n<p><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#radiotherapy\">Radiotherapy after mastectomy</a></p>\r\n<p><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#radiotherapy\">Dose fractionation for external beam radiotherapy</a></p>\r\n</td>\r\n</tr>\r\n<tr>\r\n<td width=\"35%\">\r\n<p><a href=\"https://www.nice.org.uk/guidance/CG164\">Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer</a>&nbsp;(CG164)</p>\r\n</td>\r\n<td width=\"33%\">\r\n<p>Updates planned</p>\r\n<ul>\r\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/resources/2023-surveillance-of-early-and-locally-advanced-breast-cancer-diagnosis-and-management-nice-guideline-ng101-and-advanced-breast-cancer-diagnosis-and-treatment-nice-guideline-cg81-11321031709/chapter/surveillance-decision#genetic-testing-for-people-with-early-and-locally-advanced-breast-cancer\">Genetic testing for people with early and locally advanced breast cancer</a></li>\r\n</ul>\r\n</td>\r\n<td width=\"30%\">\r\n<p>-</p>\r\n</td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h2>Methods</h2>\r\n<p>Areas for active monitoring are identified by our&nbsp;<a href=\"https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-guidelines/maintaining-and-updating-our-guideline-portfolio\">maintaining and updating our guideline portfolio process</a>&nbsp;including validation with stakeholders.</p>\r\n<p>Active monitoring is ongoing surveillance in key topic areas. It involves one or more of:</p>\r\n<ul>\r\n<li>monitoring studies in progress by systematically searching for ongoing studies and assessing the results when published</li>\r\n<li>monitoring newly published studies by continuous searching of newly published evidence</li>\r\n<li>system monitoring by systematically collating intelligence from the health and care system and working with partners to identify areas of change.</li>\r\n</ul>\r\n<p>Guideline recommendations are developed using the methods and processes in&nbsp;<a href=\"https://www.nice.org.uk/process/pmg20/chapter/introduction\">developing NICE guidelines: the manual</a>&nbsp;and the&nbsp;<a href=\"https://www.nice.org.uk/process/pmg20/resources/developing-nice-guidelines-the-manual-appendices-a-to-n-2549710189/chapter/appendix-m-interim-principles-for-methods-and-processes-for-supporting-digital-living-guideline\">interim principles for methods and processes for supporting digital living guideline recommendations</a>.</p>\r\n<p>If you have new information, intelligence or evidence relevant to any of the key topic areas listed above, please contact <a href=\"mailto:prioritisation@nice.org.uk\">prioritisation@nice.org.uk</a>.</p>","Reference":"GID-HUB10003","ProjectType":"HUB","TechnologyType":null,"ProductTypeName":"Hub","Process":"HUB","Title":"Breast cancer guidelines","Status":"InProgress","ProjectGroup":"Other","PublishedDate":null,"LastModifiedDate":"2024-01-10T11:13:01.8481931","FirstGoLiveDate":"2023-08-23T05:30:34.2603567","CreatedDate":"2023-08-16T13:19:39.3024001","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"AreasOfInterestList":[],"TopicSelectionDecision":"AwaitingDecision","TopicSelectionReason":null,"TopicSelectionDecisionDate":null,"TopicSelectionFurtherInfo":null,"IndicatorSubTypes":[]}